Standardization of cardiac markers.
Developing primary reference materials to standard cardiac biomarker assays, specifically cardiac troponin I (cTnI) and B-type natriuretic peptide (BNP), as well as develop quality specifications for immunoassays to optimize clinical use, whether for diagnostics or risk assessment, have been primary goals of the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD). The purpose of this paper is to review the current status of standardization issues for myoglobin, creatine kinase MB, cardiac troponin I and natriuretic peptides (BNP and NT-proBNP) and quality specifications for analytical immunoassays for the worldwide, consistent clinical utilization of these and future cardiac biomarkers.
Apple
Fred S
FS
Clinical Laboratories P4 Hennepin County Medical Center Minneapolis, MN 55415, USA. fred.apple@co.hennepin.mn.us
D015415:Biomarkers; D001774:Blood Chemical Analysis / Q000592:standards; D003402:Creatine Kinase / Q000097:blood; D052276:Creatine Kinase, BB Form; D006331:Heart Diseases / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D009211:Myoglobin / Q000097:blood; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D012015:Reference Standards; D019210:Troponin I / Q000097:blood
D015415:Biomarkers; D007527:Isoenzymes; D009211:Myoglobin; D010446:Peptide Fragments; D019210:Troponin I; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D003402:Creatine Kinase; D052276:Creatine Kinase, BB Form